Abstract
Research studies suggest that tumor-related angiogenesis contributes to the phenotype of malignant gliomas. We assessed the effect of local delivery of the angiogenesis inhibitor endostatin on human glioma cell line (U-87MG) xenografts. Baby hamster kidney (BHK) cells were stably transfected with a human endostatin (hES) expression vector and were encapsulated in alginate-poly L-lysine (PLL) microcapsules for long-term delivery of hES. The release of biologically active endostatin was confirmed using assays of bovine capillary endothelial (BCE) proliferation and of tube formation. Human endostatin released from the microcapsules brought about a 67.2% inhibition of BCE proliferation. Furthermore, secreted hES was able to inhibit tube formation in KDR/PAE cells (porcine aortic endothelial cells stably transfected with KDR, a tyrosine kinase) treated with conditioned U-87MG medium. A single local injection of encapsulated endostatin-secreting cells in a nude mouse model resulted in a 72.3% reduction in subcutaneous U87 xenografts' weight 21 days post treatment. This inhibition was achieved by only 150.8 ng/ml human endostatin secreted from 2 × 105 encapsulated cells. Encapsulated endostatin-secreting cells are effective for the treatment of human glioblastoma xenografts. Continuous local delivery of endostatin may offer an effective therapeutic approach to the treatment of a variety of tumor types.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Black, P.M. Brain tumor. Part 2. N. Engl. J. Med. 324, 1555–1564 (1991).
Leon, S.P., Folkerth, R.D. & Black, P.M. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77, 362–372 (1996).
Folkman, J. Angiogenesis inhibitors generated by tumors. Mol. Med. 1, 120–122 (1995).
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 ( 1996).
Kerbel, R.S. A cancer therapy resistant to resistance. Nature 390 , 335–336 (1997).
Hanahan, D. A flanking attack on cancer. Nat. Med. 4, 13–14 (1998).
Brem, S., Brem, H., Folkman, J., Finkelstein, D. & Patz, A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 36, 2807–2812 (1976).
Holmgren, L., O'Reilly, M.S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149–153 ( 1995).
Tanaka, T., Manome, Y., Wen, P., Kufe, D.W. & Fine, H.A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3, 437–442 ( 1997).
Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T. & Martuza, R.L. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34, 869–875 (1994).
Takamiya, Y., Friedlander, R.M., Brem, H., Malick, A. & Martuza, R.L. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J. Neurosurg. 78, 470–476 ( 1993).
Lee, J.K., Choi, B., Sobel, R.A., Chiocca, E.A. & Martuza, R.L. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg. 73, 429–435 ( 1990).
Tamargo, R.J., Leong, K.W. & Brem, H. Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J Neurooncol. 9, 131–138 ( 1990).
O'Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315–328 (1994).
Kirsch, M. et al. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 58, 4654–4659 (1998).
O'Reilly, M.S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).
Lim, F. & Sun, A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 210, 908– 910 (1980).
Soon-Shiong, P. et al. Insulin independence in a type 1 diabetic patient after encapsulated islets transplantation. Lancet 143, 950– 955 (1994).
Lanza, R.P., Hayes, J.L. & Chick, W.L. Encapsulated cell technology. Nat. Biotechnol. 14, 1107–1111 ( 1996).
Ismail, N., Hortelano, G. & Al-Hendy, A. Growth hormone gene therapy using Encapsulated myoblast . In Cell encapsulation technology and therapeutics. (eds Kuhetreiber, W.M., Lanza, R.P. & Chick, W.L.) 343– 350 (Birkhauser, Boston, MA; 1999).
Machluf, M., Orsola, A. & Atala, A. Controlled release of therapeutic agents: slow delivery and cell encapsulation. World J. Urol. 18, 80–83 (2000).
Savelkoul, H.F.J. et al. Modulation of systemic cytokine levels by implantation of alginate-encapsulated cells. J. Immunol. Methods 170 , 185–196 (1994).
Machluf, M., Regev, O., Peled, Y., Kost, J. & Cohen, S. Characterization of microencapsulated liposome systems for the controlled delivery of liposome-associated macromolecules. J. Contr. Release 43, 35–45 (1996).
Prakash, S. & Chang, T.M.S. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat. Med. 2, 883–887 (1996).
Gasper, L.E. et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biol. Phys. 24, 55–57 (1992).
Liang, B.C., Thornton, A.F. Jr., Sandler, H.M. & Greenberg, H.S. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J. Neurosurg. 75, 559–563 (1991).
Sneed, P.K. et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int. J. Radiat. Oncol. Biol. Phys. 29, 719–727 ( 1994).
O'Reilly, M.S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice . Nat. Med. 2, 689–692 (1996).
Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404– 407 (1997).
Fenstermacher, J.D., Blasberg, R.G. & Patlak, C.S. Methods for quantifying the transport of drugs across brain barrier systems. Pharmacol. Ther. 14, 217–248 (1981).
Jain, R.K. Haemodynamic and transport barriers to the treatment of solid tumours. Int. J. Radiat. Biol. 60, 85–100 (1991).
Yamaguchi, N. et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18, 4414–4423 (1999).
Blezinger, P. et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17, 343–348 ( 1999).
Chartier, C., Degryse, M., Dieterle, A., Pavirani, A. & Mehtali, M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 113, 178–183 ( 1991).
Deroanne, C.F., Hajitou, A., Calberg-Bacq, C.M., Nusgens, B.V. & Lapiere, C.M. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res. 57, 5590–5597 (1997).
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. & Heldin, C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988 –26995 (1994).
Carroll, R.S. et al. KDR activation in astrocytic neoplasms. Cancer. 7, 1335–1341 ( 1999).
Weidner, N., Semple, J.P., Welch, W.R. & Folkman, J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma . N. Engl. J. Med. 324, 1– 8 (1991).
Acknowledgements
We wish to thank Dr. Judah Folkman for his helpful suggestions in the preparation of the manuscript. This work is supported by a grant from the Boston Neurosurgical Foundation. T.J. is a recipient of a fellowship from Jikei University School of Medicine.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joki, T., Machluf, M., Atala, A. et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 19, 35–39 (2001). https://doi.org/10.1038/83481
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/83481
This article is cited by
-
Macroscale biomaterials strategies for local immunomodulation
Nature Reviews Materials (2019)
-
Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth
Scientific Reports (2017)
-
Production of guluronate oligosaccharide of alginate from brown algae Stypocaulon scoparium using an alginate lyase
Journal of Applied Phycology (2017)
-
The structure and dynamics of Nano Particles encapsulated by the SDS monolayer collapse at the water/TCE interface
Scientific Reports (2016)
-
A novel multilayer immunoisolating encapsulation system overcoming protrusion of cells
Scientific Reports (2014)